We leveraged HTA-2.0, a newer generation of microarray that interrogates junctions between exons in the transcriptome as well as the exon themselves and RNA-Seq analysis to test whether modulating AR signaling would alter ASE prostate cancer cells. Here, AR is linked to prostate carcinoma.